IFP Advisors Inc Acquires 7,455 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

IFP Advisors Inc increased its holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 170.4% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 11,831 shares of the company’s stock after purchasing an additional 7,455 shares during the period. IFP Advisors Inc’s holdings in Recursion Pharmaceuticals were worth $80,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of RXRX. Axxcess Wealth Management LLC boosted its stake in Recursion Pharmaceuticals by 4.3% during the third quarter. Axxcess Wealth Management LLC now owns 43,884 shares of the company’s stock worth $289,000 after buying an additional 1,795 shares during the period. Wedmont Private Capital boosted its stake in Recursion Pharmaceuticals by 10.6% during the fourth quarter. Wedmont Private Capital now owns 20,943 shares of the company’s stock worth $144,000 after buying an additional 2,000 shares during the period. Green Alpha Advisors LLC boosted its stake in Recursion Pharmaceuticals by 3.6% during the fourth quarter. Green Alpha Advisors LLC now owns 67,145 shares of the company’s stock worth $454,000 after buying an additional 2,346 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Recursion Pharmaceuticals by 5.3% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 52,530 shares of the company’s stock worth $346,000 after buying an additional 2,667 shares during the period. Finally, KBC Group NV boosted its stake in Recursion Pharmaceuticals by 79.9% during the third quarter. KBC Group NV now owns 7,602 shares of the company’s stock worth $50,000 after buying an additional 3,377 shares during the period. Institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Stock Up 1.7 %

Shares of RXRX opened at $6.58 on Thursday. The firm has a market capitalization of $2.57 billion, a P/E ratio of -4.30 and a beta of 0.86. Recursion Pharmaceuticals, Inc. has a 12-month low of $5.60 and a 12-month high of $12.36. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. The firm has a fifty day moving average price of $7.68 and a 200-day moving average price of $7.08.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its earnings results on Friday, February 28th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.17). The company had revenue of $4.60 million for the quarter, compared to analysts’ expectations of $19.04 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The firm’s revenue for the quarter was down 57.8% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.42) earnings per share. Equities research analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. Leerink Partners dropped their price objective on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating for the company in a research note on Friday, February 28th. Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 price objective on shares of Recursion Pharmaceuticals in a research note on Thursday, February 6th. Cowen reissued a “hold” rating on shares of Recursion Pharmaceuticals in a research note on Friday, February 28th. Finally, KeyCorp lowered their target price on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a research note on Wednesday, January 8th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, Recursion Pharmaceuticals has an average rating of “Hold” and a consensus target price of $8.25.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.